# Aortic Stenosis Intervention Thresholds

Replace the valve promptly for symptomatic severe aortic stenosis or LVEF below 50%; in apparently asymptomatic disease, confirm severity and use exercise testing, velocity progression, BNP, and life expectancy to determine whether surveillance remains appropriate.

**Clinical question:** Which patients with aortic stenosis need valve replacement now, and how should TAVR versus SAVR be selected?

Updated: 2026-09-15T17:53:31.062424+00:00

## What matters in practice
- Proceed to aortic valve replacement for severe AS with symptoms or LVEF below 50%; do not defer intervention solely because symptoms are underreported. [2]
- Concordant severe AS is defined by Vmax at least 4.0 m/s, mean gradient at least 40 mm Hg, and AVA at most 1.0 cm²; AVA indexed at most 0.6 cm²/m² improves specificity in patients with low body surface area. [1][9][21]
- For AVA below 1.0 cm² with mean gradient below 40 mm Hg, first exclude Doppler/LVOT measurement error and define flow using stroke-volume index below 35 mL/m²; CT valve calcium scoring can confirm anatomic severity. [19][20][21]
- In asymptomatic severe AS with preserved LVEF, AVR is reasonable after an abnormal exercise test, BNP greater than three times the upper limit of normal, Vmax above 5 m/s, or Vmax progression of at least 0.3 m/s per year. [2]
- For U.S. procedure selection, SAVR is favored in patients younger than 65 years or with life expectancy over 20 years, whereas TAVR is favored in those older than 80 years or with life expectancy under 10 years. [4][5]
- Bicuspid valve anatomy requires individualized Heart Team selection: exploratory low-risk data in patients 70 years or younger found higher 1-year death, stroke, or rehospitalization with TAVR versus SAVR in the bicuspid subgroup. [12]

## Confirm that stenosis is truly severe before assigning an intervention threshold

Use integrated Doppler and valve-area data rather than a single echocardiographic measurement.

Classify AS as severe when transthoracic echocardiography shows Vmax at least 4.0 m/s, mean transvalvular gradient at least 40 mm Hg, and AVA at most 1.0 cm². A dimensionless index of 0.25 or less is an additional severe-AS marker. In a patient with small body size, an indexed AVA of 0.6 cm²/m² or less increases specificity for severe stenosis. [1][9][11][21]

Before labeling discordant AS as low-gradient severe disease, repeat or review the study for LVOT diameter and LVOT velocity-time integral acquisition, and ensure interrogation from nonapical windows. LVOT undermeasurement falsely reduces calculated AVA; low flow can lower Vmax and gradient despite severe fixed obstruction. Conversely, anemia, hyperthyroidism, concomitant aortic regurgitation, and other hyperdynamic states can increase gradients, while pressure recovery can overestimate severity when the sinotubular junction is under 30 mm. [11][21][22]

An AVA below 1.0 cm² with mean gradient below 40 mm Hg occurs in approximately 20% to 30% of studies. This is not an automatic AVR indication: establish whether the patient has low flow, verify anatomic severity, then attribute symptoms before proceeding. [19][20]
- Concordant high-gradient severe AS: AVA at most 1.0 cm² plus mean gradient at least 40 mm Hg or Vmax at least 4.0 m/s. [1][9][21]
- Low flow: stroke-volume index below 35 mL/m²; flow rate at most 200 mL/s is another low-flow criterion used in stress-echo classification. [20]
- Normal-flow discordance: stroke-volume index at least 35 mL/m² with AVA below 1.0 cm² and mean gradient below 40 mm Hg; recheck acquisition before escalating to intervention. [19]

*Echocardiographic thresholds that determine whether AS is concordantly severe or requires discordance adjudication. [1][9][11][19][20][21]*

| Pattern | Required findings | Immediate next step |
| --- | --- | --- |
| Concordant severe AS | Vmax ≥4.0 m/s, mean gradient ≥40 mm Hg, and AVA ≤1.0 cm²; dimensionless index ≤0.25 supports severity. [1][9][11][21] | Determine symptom status and LVEF; symptomatic disease or LVEF <50% meets the principal AVR threshold. [2] |
| Classical low-flow, low-gradient AS | AVA <1.0 cm², mean gradient <40 mm Hg, LVEF <50%, stroke-volume index <35 mL/m², and flow rate ≤200 mL/s. [20] | Use low-dose dobutamine stress echocardiography to distinguish true severe from pseudo-severe AS. [20] |
| Paradoxical low-flow, low-gradient AS | AVA <1.0 cm², mean gradient <40 mm Hg, LVEF ≥50%, stroke-volume index <35 mL/m², and flow rate ≤200 mL/s. [20] | Confirm severity with stress echocardiography or CT aortic valve calcium scoring after checking echo measurements. [21] |
| Discordant normal-flow AS | Typically AVA <1.0 cm² with mean gradient <40 mm Hg and stroke-volume index ≥35 mL/m². [19] | Correct technical or loading-condition explanations; use CT calcium scoring when uncertainty persists. [19][22] |

## Resolve low-gradient severe AS with stress echocardiography or CT calcium scoring

The test choice depends primarily on LVEF, flow state, and whether Doppler discordance persists after technical review.

In low-flow, low-gradient AS with reduced LVEF, perform low-dose dobutamine stress echocardiography when clinically stable and images permit. True severe AS is supported when mean gradient rises above 40 mm Hg while AVA remains below 1.0 cm². A substantial increase in AVA with flow favors pseudo-severe stenosis and redirects evaluation toward the cause of reduced LV systolic function rather than immediate valve replacement. [20]

In discordant AS after measurement review, noncontrast CT aortic valve calcium scoring provides an anatomic severity check independent of flow. Severe AS is unlikely below 800 Agatston units in women or 1,600 in men, is possible above 1,200 in women or 2,000 in men, and is highly likely above 1,600 in women or 3,000 in men. Earlier validated thresholds near 1,250 to 1,275 AU in women and 2,000 to 2,065 AU in men are also used; interpret borderline values in the full clinical and echocardiographic context. [9][19][21]

Once symptomatic low-gradient disease is confirmed as truly severe, treat it with AVR using the same intervention principle applied to classic severe AS. Do not use CT calcium scoring alone to establish that symptoms are valve-related; reconcile symptoms with ventricular function, flow state, and competing cardiopulmonary disease. [19]
- Choose dobutamine stress echocardiography for reduced-EF low-flow, low-gradient AS when the key uncertainty is fixed severe obstruction versus pseudo-severe AS. [20]
- Choose CT calcium scoring when Doppler values remain discordant after technical review, particularly in preserved-EF paradoxical low-flow disease. [19][21]
- Avoid interpreting a single discordant AVA as a stand-alone AVR trigger. LVOT measurement error and load-dependent gradients are common causes of discordance. [11][21][22]

*CT aortic valve calcium score ranges for adjudicating discordant AS severity. [9][19][21]*

| Likelihood of severe AS | Women | Men | Decision use |
| --- | --- | --- | --- |
| Unlikely | <800 AU. [9][21] | <1,600 AU. [9][21] | Seek measurement error, pseudo-severe AS, or an alternative explanation for symptoms. [21][22] |
| Possible | >1,200 AU. [9][21] | >2,000 AU. [9][21] | Integrate flow state, symptoms, repeat echo quality, and valve morphology before committing to AVR. [9][21] |
| Highly likely | >1,600 AU. [9][21] | >3,000 AU. [9][21] | If symptoms are attributable to AS, manage as confirmed severe low-gradient AS and evaluate for AVR. [19][21] |

## When to replace the valve in symptomatic and asymptomatic severe AS

Symptoms, LVEF, and objective high-risk markers determine the timing decision after severe AS is confirmed.

For confirmed severe AS, AVR is recommended when the patient has symptoms or LVEF below 50%. Elicit exertional dyspnea, angina, presyncope, syncope, and activity restriction against prior functional capacity; patients who have reduced activity may deny symptoms despite clinically important limitation. In low-gradient disease, intervene only after confirming true severe stenosis and linking symptoms to the valve lesion. [2][19]

For apparently asymptomatic severe AS with LVEF above 50% to 55%, obtain exercise testing when safe and feasible to unmask exertional symptoms or an abnormal physiologic response. A positive stress test is a guideline-supported reason to consider AVR rather than defaulting to surveillance. Clinical trials informing early intervention commonly confirmed asymptomatic status with low-level stress testing, although trial populations and procedure strategies differed. [2]

Additional triggers that make AVR reasonable in asymptomatic severe AS are BNP greater than three times the upper limit of normal, very severe stenosis with Vmax above 5 m/s, Vmax increase of at least 0.3 m/s per year, or another indication for open-heart surgery. Outside these features, clinical surveillance followed by delayed AVR remains the guideline default described in current reviews. [2]

Randomized evidence increasingly supports early SAVR or TAVR in selected asymptomatic severe AS, but this does not eliminate the need to verify that the patient is truly asymptomatic, that stenosis is severe, and that procedural choice is durable and anatomically suitable. Apply early-intervention data through multidisciplinary valve evaluation rather than treating every asymptomatic Doppler-defined severe lesion identically. [2][6]
- Replace now: confirmed severe AS plus attributable symptoms, or LVEF <50%. [2]
- Consider early AVR despite no spontaneous symptoms: positive exercise test, BNP >3 times upper limit of normal, Vmax >5 m/s, Vmax rise ≥0.3 m/s/year, or concomitant cardiac-surgery indication. [2]
- Continue structured surveillance when none of these triggers is present and LVEF is preserved, while reassessing symptoms, ventricular function, and AS progression. [2]

*Timing thresholds for AVR after confirmation of severe AS. [2][6][19]*

| Clinical state | Threshold | Timing decision |
| --- | --- | --- |
| Symptomatic severe AS | Symptoms attributable to confirmed severe AS. [2][19] | Proceed to AVR evaluation without watchful waiting. [2] |
| Severe AS with LV systolic dysfunction | LVEF <50%, including patients without reported symptoms. [2] | Proceed to AVR evaluation. [2] |
| Apparently asymptomatic severe AS, preserved LVEF | Positive exercise test, BNP >3× upper limit of normal, Vmax >5 m/s, Vmax increase ≥0.3 m/s/year, or other cardiac-surgery indication. [2] | Early AVR is reasonable after procedural and lifetime-management assessment. [2] |
| Apparently asymptomatic severe AS without high-risk trigger | LVEF >50% to 55% and no listed high-risk criterion. [2] | Clinical surveillance with delayed AVR when an intervention threshold emerges. [2] |

## Select TAVR or SAVR using age, life expectancy, anatomy, and bicuspid morphology

Procedure selection is a lifetime valve-management decision, not a surgical-risk calculation alone.

ACC/AHA age and life-expectancy thresholds favor SAVR for patients younger than 65 years or with anticipated survival beyond 20 years, and favor TAVR for patients older than 80 years or with anticipated survival under 10 years. Patients between these groups require individualized assessment of transfemoral feasibility, native-valve anatomy, coexisting surgical disease, and the expected consequences of future valve interventions. [4][5]

For severe symptomatic AS, transfemoral TAVR is the preferred TAVR access approach when feasible; alternative access may be considered when transfemoral access is unsuitable. Procedural choice should be made by a Heart Team and dedicated valve center, particularly when anatomy, access, or competing surgical indications complicate the decision. [15][17]

For low-risk patients aged 60 to 75 years with tricuspid or bicuspid AS, NOTION-2 reported similar 3-year clinical outcomes with TAVR and SAVR. This midterm equivalence should not be interpreted as durability equivalence for all younger patients, because long-term follow-up remains limited in younger low-risk populations. [4][5]

Bicuspid AS deserves additional caution. Randomized TAVR-versus-SAVR trials in bicuspid disease have historically been lacking, and an exploratory NOTION-2 substudy in low-risk patients 70 years or younger found a higher 1-year risk of death, stroke, or rehospitalization after TAVR in the bicuspid subgroup, with an absolute risk difference of 13.8% (95% CI, 1.2% to 26.3%). Favor SAVR when bicuspid anatomy and expected longevity make procedural durability and anatomy especially consequential, unless individualized assessment supports TAVR. [3][12][13]

Tradeoffs should be explicit. In a propensity-matched administrative analysis of bicuspid AS, TAVR and SAVR had similar in-hospital mortality, while TAVR was associated with less acute myocardial infarction, postoperative bleeding, vascular complications, discharge to a nursing facility, and shorter hospitalization; TAVR had more complete heart block and permanent pacemaker implantation. These observational findings guide discussion but do not replace randomized evidence in bicuspid anatomy. [3]
- Favor SAVR: age <65 years, life expectancy >20 years, or anatomy and concomitant operative needs that favor open surgery. [4][5]
- Favor TAVR: age >80 years, life expectancy <10 years, and feasible transfemoral access. [4][5][15]
- Treat bicuspid morphology as a separate procedural-selection branch; discuss the exploratory adverse bicuspid signal in younger low-risk TAVR recipients. [12]

*Practical AVR modality selection thresholds and evidence-sensitive exceptions. [3][4][5][12][15]*

| Factor | Direction of choice | Decision implication |
| --- | --- | --- |
| Age <65 years or life expectancy >20 years | SAVR favored. [4][5] | Prioritize surgical valve strategy and long-term lifetime management. [4][5] |
| Age >80 years or life expectancy <10 years | TAVR favored. [4][5] | Assess transfemoral feasibility first. [15] |
| Age 60-75 years, low surgical risk | Either TAVR or SAVR may be appropriate after individualized assessment. [4][5] | NOTION-2 reported similar 3-year clinical outcomes; account for limited long-term data in younger patients. [4][5] |
| Bicuspid AS in low-risk patients ≤70 years | SAVR often warrants strong consideration. [12] | Exploratory data found higher 1-year death, stroke, or rehospitalization with TAVR; absolute risk difference 13.8%. [12] |
| Feasible transfemoral access | Supports TAVR when patient-level criteria favor it. [15] | Use transfemoral access preferentially among TAVR approaches. [15] |

## Surveillance should actively search for a new AVR trigger

Watchful waiting is appropriate only when it is structured around symptoms, ventricular function, and hemodynamic progression.

For asymptomatic severe AS without an early-intervention trigger, continue clinical surveillance rather than passive observation. At each reassessment, document exertional capacity, repeat LVEF assessment, compare Vmax with prior studies, and obtain BNP when its result would alter the timing decision. Escalate to AVR evaluation if LVEF falls below 50%, exercise testing becomes positive, BNP exceeds three times the upper limit of normal, Vmax exceeds 5 m/s, or Vmax rises by at least 0.3 m/s per year. [2]

Repeat echo interpretation must account for changing flow state and acquisition quality. A new AVA-gradient discrepancy should prompt reassessment of LVOT measurement, Doppler windows, blood pressure and loading conditions, stroke-volume index, and, when unresolved, CT calcium scoring or stress echocardiography according to the low-gradient phenotype. [11][19][20][21][22]

Refer patients reaching an intervention threshold to a multidisciplinary valve program before the procedure choice is finalized. The referral should include symptom and exercise-test documentation, complete Doppler data, LVEF, flow classification, CT calcium data when obtained, vascular-access assessment for TAVR, and valve morphology, particularly bicuspid anatomy. [15][17]
- Do not wait for spontaneous symptom disclosure in an activity-limited patient; use exercise testing to clarify asymptomatic status when feasible. [2]
- Treat Vmax progression of at least 0.3 m/s/year as a timing signal, not merely a descriptive echo change. [2]
- Reopen the severity assessment when serial echo values become discordant rather than attributing the difference automatically to disease progression. [19][21][22]

*Escalation triggers during surveillance of confirmed severe AS with initially preserved LVEF. [2]*

| Finding on follow-up | Threshold | Next action |
| --- | --- | --- |
| New LV systolic dysfunction | LVEF <50%. [2] | Refer for AVR evaluation. [2] |
| Exercise test abnormality | Positive stress test. [2] | Consider early AVR rather than continued surveillance. [2] |
| BNP elevation | >3× upper limit of normal. [2] | Consider early AVR after confirming severe AS and overall procedural suitability. [2] |
| Very severe hemodynamics | Vmax >5 m/s. [2] | Consider early AVR. [2] |
| Rapid progression | Vmax increase ≥0.3 m/s/year. [2] | Consider early AVR. [2] |

## References
1. Association of Time Between Left Ventricular and Aortic Systolic ... — jamanetwork.com — https://jamanetwork.com/journals/jamacardiology/fullarticle/2731733
2. Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Is Enthusiasm Exceeding the Evidence? — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.03.002
3. Temporal Trends and Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2019.06.037
4. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.076678?doi=10.1161%2FCIRCULATIONAHA.125.076678
5. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.076678
6. Early Aortic Valve Replacement of Asymptomatic Severe Aortic ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.125.041283
7. Abstract 4147770: TAVR versus SAVR for Severe Aortic Stenosis in ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circ.150.suppl_1.4147770
8. 2026 Arthur E. Weyman Young Investigator's Award... - Ovid — journals.lww.com — https://journals.lww.com/00002144-202608000-00018
9. Discordance between aortic valve gradient and area : European Heart Journal Supplements — journals.lww.com — https://journals.lww.com/00125819-202500003-00024
10. Discordance in Grading Methods of Aortic Stenosis by Pre ... — journals.lww.com — https://journals.lww.com/anesthesia-analgesia/pdf/10.1213/ane.0000000000001099~discordance-in-grading-methods-of-aortic-stenosis-by
11. A computer vision model for the identification... : Cardiovascular Diagnosis and Therapy — journals.lww.com — https://journals.lww.com/cdt/_layouts/15/oaks.journals/downloadpdf.aspx?an=01661525-202412000-00011
12. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis aged 70 years or younger: A NOTION-2 substudy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0002870325000341
13. Transcatheter and Surgical Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Stenosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0003497522009419
14. Contemporary Management of Aortic Stenosis: Timing of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/eci.70245
15. Interventional therapies for chronic heart failure: An overview of recent developments - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11911643
16. Diretriz Brasileira de Fibrilação Atrial – 2025 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13400077
17. De Ritis (AST/ALT) ratio as a predictor of early adverse outcomes following transcatheter aortic valve replacement — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13411933
18. BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A MIXED-METHODS STUDY - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11862211
19. Aortic valve stenosis: evaluation and management of patients with discordant grading — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-15/Aortic-valve-stenosis-evaluation-and-management-of-patients-with-discordant-grading
20. Exercise and pharmacological testing combined with echocardiography in the diagnosis of aortic valve stenosis — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-18/exercise-and-pharmacological-testing-combined-with-echocardiography-in-the-diagn
21. Asymptomatic patients with aortic valve stenosis: diagnosis criteria — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/education/cardiopractice/asymptomatic-patients-with-aortic-valve-stenosis-diagnosis-criteria
22. The value of echocardiography in aortic valve disease: the essentials — www.escardio.org — https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-18/the-value-of-echocardiography-in-aortic-valve-disease-the-essentials
23. [PDF] Heart valve disease presenting in adults - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng208/evidence/e-stress-testing-and-stress-echocardiography-in-determining-need-for-intervention-pdf-10887602658
24. 2020 ACC/AHA Guideline for the Management of Patients With ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.1161%2FCIR.0000000000000923&link_type=DOI

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.